Marine Hug de Larauze

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

Thierry André, Déwi Vernerey, Laurent Mineur et al. · Journal of Clinical Oncology · 2018 · 169 citations

Dfs Events, Surgical Oncology, Oncology +14

Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study

Momar Diouf, Benoist Chibaudel, Thomas Filleron et al. · Health and Quality of Life Outcomes · 2014 · 32 citations · Full text

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

Benoist Chibaudel, Franck Bonnetain, Christophe Tournigand et al. · BMC Cancer · 2015 · 22 citations · Full text

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial

Zeinab Hamidou, Benoist Chibaudel, Mohamed Hebbar et al. · PLoS ONE · 2016 · 17 citations · Full text

Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer

Alexandra Lapeyre-Prost, Marine Hug de Larauze, Benoist Chibaudel et al. · Clinical Colorectal Cancer · 2015 · 14 citations · Full text

Oxaliplatin Combination Chemotherapy, Surgical Oncology, Gastrointestinal Oncology +6